Aspire Biopharma Reports Positive Sublingual Aspirin Study Results, Shares Surge Ahead of Market Open

Aspire Biopharma reported positive results from a sublingual aspirin study, causing shares to jump pre-bell. The company's focus on video gaming, gaming adjacent, and new metaverse video gaming businesses has garnered attention. PowerUp Acquisition Corp., a blank check company, is also in the spotlight, with plans to search for a business combination target within the interactive media, digital media, sports, entertainment, and leisure industries.

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) reported positive results from a clinical trial of its sublingual aspirin product, causing shares to jump pre-bell. The company's focus on video gaming, gaming adjacent, and new metaverse video gaming businesses has also garnered attention.

The clinical trial, AB-101, compared Aspire's investigational sublingual aspirin product to chewed uncoated aspirin tablets in healthy adults. The study found that Aspire's sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA) compared to chewed aspirin tablets (p0.05). The product was safe and well-tolerated by patients, with no adverse events reported [1].

The sublingual route of administration offers several benefits over standard oral aspirin, including faster absorption through the blood vessels directly, bypassing first-pass metabolic processes, and avoiding exposure to the harsh acidic environment of the stomach and digestive enzymes. These advantages could lead to a faster onset of action and reduced drug-food and drug-drug interactions [1].

Aspire Biopharma is developing its investigational sublingual aspirin product for the treatment of suspected acute myocardial infarction (AMI), a major cause of death affecting nearly 3 million Americans each year and resulting in over a million deaths. The company plans to review the clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval [1].

In addition to its focus on healthcare, Aspire Biopharma has also been involved in the video gaming industry. The company's recent acquisition of PowerUp Acquisition Corp. has brought attention to its plans to search for a business combination target within the interactive media, digital media, sports, entertainment, and leisure industries [2].

Aspire Biopharma's stock price has been volatile in recent months, with shares trading in the range of $3.00 to $4.50. The company's positive clinical trial results and expansion into new industries may provide investors with new opportunities for growth.

References:
[1] https://finance.yahoo.com/news/aspire-biopharma-announces-positive-top-123000711.html
[2] https://www.powerupacquisition.com/